1. A. D. Rodrigues (ed.). In Drug–Drug Interactions. Drugs and the Pharmaceutical Sciences, 116. Marcel Dekker, New York, 2002.
2. FDA. Guidance for Industry: Drug interaction studies—study design, data analysis and implications for dosing and labelling. Available at: http://www.fda.gov/cder/guidance/index.htm.
3. O. V. Trubetskoy, J. R. Gibson, and B. D. Marks. Highly miniaturized formats for in vitro drug metabolism assays using Vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J. Biomol. Screen. 10(1):56–66 (2005).
4. C. L. Crespi, V. P. Miller, and D. M. Stresser. Design and Application of Fluorogenic Assays for Human Cytochrome P450 Inhibition. In E. F. Johnson, and M. R. Waterman (eds.), Cytochrome P450, Part C. Vol 357, Academic Press, London, 2002.
5. J. J. Cali, D. Ma M. Sobol et al. Luminogenic cytochrome P450 assays. Expert Opin. Drug Metab. Toxicol. 2(4):629–645 (2006).